immunotherapy

Amfani da Immunotherapy don Magance Ciwon daji na Late-Stage

  Gabatarwa Immunotherapy ya zama hanya mai ban sha'awa a cikin maganin ciwon daji, musamman don maganin ciwon daji na mataki-mataki wanda ya nuna ƙarancin tasiri tare da daidaitattun magunguna. Wannan sabuwar appr..

Tumor-Infiltrating Lymphocyte (TIL) Therapy a kasar Sin

Feb 2024: Tumor-infiltrating lymphocyte (TIL) therapy treatment is a potential method that utilizes the body's immune system to fight solid tumors. This therapeutic area in China is advancing rapidly because of the nation's incr..

Maganin Ciwon daji Kyauta A China Ba tare da Karya Banki ba: Jagora Ga Masu Bukatarsa

Maganin kansar kyauta a kasar Sin yana ba da bege da warkarwa ga mutanen da ke bukata. Don haka, idan ba za ku iya zaɓar maganin kansa ba saboda yawan kuɗin sa, wannan jagorar an yi muku musamman. Gano yadda ake renon organiz..

Matsayin Immunotherapy A cikin Jiyya na Lymphoma

Idan kana karanta wannan, kai ko watakila ɗaya daga cikin masoyinka yana kan tafiya wanda babu wanda ya taɓa shirin ɗauka-hanyar fuskantar ciwon daji. Mun fahimci cewa wannan hanyar tana cike da rashin tabbas, tsoro, da lokacin da ta ji..

TIL rigakafi, Farashin TIL, Tumor Infiltrating Lymphocytes

Tumor Infiltrating lymphocytes (TIL) Immunotherapy a Indiya

Afrilu 2023: Yin amfani da tsarin garkuwar jiki don yaƙar ƙwayoyin cutar kansa shine makasudin hanyar maganin cutar kansa da aka sani da ƙari infiltrating lymphocytes (TIL) immunotherapy. Tsarin ya ƙunshi ɗaukar ƙwayoyin rigakafi da ake kira TI.

Americanungiyar Hematology ta Amurka, Karteyva, Sin, JW Therapeutics, relmacabtagene autoleucel

JW Therapeutics Yana Gabatar da Sabbin Bayanan Clinical akan Carteyva® a cikin Follicular Lymphoma da Mantle Cell Lymphoma a Taron Shekara-shekara na ASH na 64th

SHANGHAI, CHINA, Disamba 12, 2022 Wani kamfani mai zaman kansa kuma mai ƙirƙira na fasahar kere kere mai suna JW Therapeutics (HKEX: 2126) yana mai da hankali kan haɓakawa, ƙira, da siyar da samfuran rigakafin ƙwayoyin cuta. A taron jama'ar Amirka na 64.

Cell far, Sin, JW Therapeutics, Shanghai

JW Therapeutics Ya Sanar da Cewa Magungunan Immunotherapy Kwayoyinsa sun Yi Nasarar Amfani da Marasa lafiya 300

SHANGHAI, CHINA, Nuwamba 9, 2022 - JW Therapeutics (HKEX: 2126), wani kamfani mai zaman kansa kuma mai haɓaka fasahar kere kere wanda ke mai da hankali kan haɓakawa, masana'antu, da kasuwancin samfuran rigakafin ƙwayoyin cuta, ya sanar da cewa kamar yadda N..

2 saba'in bio, Sin, immunotherapy, JW Therapeutics, Partnership

JW Therapeutics da 2 saba'in bio sun Sanar da Haɗin gwiwar Dabarun don Haɓaka Bincike da Haɓaka Magunguna na tushen T-cell

SHANGHAI, CHINA da CAMBRIDGE, MASSACHUSETTS, US, Oktoba 27, 2022 - JW Therapeutics (HKEX: 2126), wani kamfani mai zaman kansa kuma mai haɓaka fasahar kere kere wanda ke mai da hankali kan haɓakawa, masana'anta, da tallan rigakafin ƙwayoyin cuta.

KEYTRUDA, Merck, Pembrolizumab, Roche Tissue Diagnostics, Tsarin Kiwon Lafiya na Ventana

An amince da Pembrolizumab don ci gaba da ciwon daji na endometrial

Afrilu 2022: Hukumar Abinci da Magunguna ta amince da Pembrolizumab (Keytruda, Merck) a matsayin wakili ɗaya ga marasa lafiya da ke fama da ciwon daji na endometrial wanda ke da rashin zaman lafiya-high (MSI-H) ko gyara rashin daidaituwa.

PD-1 mai hanawa immunotherapy don B cell lymphoma

Binciken da Young, MD, Anderson Cancer Center, Amurka suka rubuta sun bayyana yadda ake amfani da PD-1 inhibitor immunotherapy a cikin B-cell lymphoma. (Jini. Sigar kan layi a ranar Nuwamba 8, 2017. Doi: 10.1182 / jini-2017-07-740993.) PD-1 immunity ..